nach oben

Journal of Neurology

Erschienen in:

25.01.2018 | Review

Myasthenia gravis and infectious disease

verfasst von: Nils Erik Gilhus, Fredrik Romi, Yu Hong, Geir Olve Skeie

Erschienen in: Journal of Neurology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Myasthenia gravis (MG) is an autoimmune disease with muscular weakness as the only symptom, and often with immunosuppressive treatment. All these aspects could have relevance for the risk of infections as well as their prophylactic and curative treatment.

Methods

This is a review article, where Web of Science has been searched for relevant key words and key word combinations. Full papers were selected first by title and then by abstract.

Results and conclusions

MG can be triggered and worsened by infections. No virus or other pathogen has been proven to have a specific link to MG. Treatment with immunosuppressive drugs and thymectomy implies a slightly increased risk for infections. Infections should be actively treated, but a few antibiotics are avoided due to potential interference with neuromuscular transmission. Hospitalization and intensive care may be necessary during infections because of MG deterioration and risk of insufficient respiration. Vaccinations are generally recommended in MG, but live microorganisms should be avoided if possible in immunosuppressed patients.

Abreu C, Sarmento A, Magro F (2017) Screening, prophylaxis and counselling before the start of biological therapies: a practical approach focused on IBD patients. Dig Liver Dis 49:1289–1297CrossRefPubMed

Andersen JB, Heldal AT, Engeland A, Gilhus NE (2014) Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand 129:26–31CrossRef

Andersen JB, Owe JF, Engeland A, Gilhus NE (2014) Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. Eur J Neurol 21:948–955CrossRefPubMedPubMedCentral

Auriel E, Regev K, Dori A, Karni A (2011) Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. Muscle Nerve 43:893–894CrossRefPubMed

Bach JF (2012) The etiology of autoimmune diseases: the case of myasthenia gravis. Annals N Y Acad Sci 1274:33–39CrossRef

Barzago C, Lum J, Cavalcante P, Srinivasan KG, Faggiani E, Camera G, Bonanno S, Andreetta F, Antozzi C, Baggi F, Calogero RA, Bernasconi P, Mantegazza R, Mori L, Zolezzi F (2016) A novel infection- and inflammation(_)associated molecular signature in peripheral blood of myasthenia gravis patients. Immunobiology 221:1227–1236CrossRefPubMed

Berrih-Aknin S, Le Panse R (2014) Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 52:90–100CrossRefPubMed

Bhattacharyya S, Darby R, Berkowitz AL (2014) Antibiotic-induced neurotoxicity. Current infectious disease reports 16

Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P (2015) Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci 22:1164–1169CrossRefPubMed

10.

Bonvalet M, Ollila HM, Ambati A, Mignot E (2017) Autoimmunity in narcolepsy. Curr Opin Pulm Med 23:522–529CrossRefPubMed

11.

Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P, Rituximab Consensus Expert C (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909–920CrossRefPubMedPubMedCentral

12.

Cavalcante P, Galbardi B, Franzi S, Marcuzzo S, Barzago C, Bonanno S, Camera G, Maggi L, Kapetis D, Andreetta F, Biasiucci A, Motta T, Giardina C, Antozzi C, Baggi F, Mantegazza R, Bernasconi P (2016) Increased expression of toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein–Barr virus infection. Immunobiology 221:516–527CrossRefPubMed

13.

Cavalcante P, Serafini B, Rosicarelli B, Maggi L, Barberis M, Antozzi C, Berrih-Aknin S, Bernasconi P, Aloisi F, Mantegazza R (2010) Epstein–Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 67:726–738PubMed

14.

Chahin S, Berger JR (2015) A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. J Neurovirol 21:623–631CrossRefPubMed

15.

Cheng DR, Barton R, Greenway A, Crawford NW (2016) Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients. Expert Rev Vaccines 15:1567–1574CrossRefPubMed

16.

Christopoulos P, Fisch P (2016) Acquired T-cell immunodeficiency in thymoma patients. Crit Rev Immunol 36:315–327CrossRefPubMed

17.

Csuka D, Czirjak L, Hobor R, Illes Z, Banati M, Rajczy K, Tordai A, Fust G (2013) Effective humoral immunity against diphtheria and tetanus in patients with systemic lupus erythematosus or myasthenia gravis. Mol Immunol 54:453–456CrossRefPubMed

18.

Dixon WG, Kezouh A, Bernatsky S, Suissa S (2011) The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case–control study. Ann Rheum Dis 70:956–960CrossRefPubMedPubMedCentral

19.

Eddy S, Wim R, Peter V, Tanja R, Jan T, Werner V (1999) Myasthenia gravis—another autoimmune disease associated with hepatitis C virus infection. Dig Dis Sci 44:186–189CrossRefPubMed

20.

Fardet L, Petersen I, Nazareth I (2016) Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. Plos Med 13(5):e1002024. https://doi.org/10.1371/journal.pmed.1002024 CrossRefPubMedPubMedCentral

21.

Feldman CH, Marty FM, Winkelmayer WC, Guan HS, Franklin JM, Solomon DH, Costenbader KH, Kim SC (2017) Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medications. Arthritis Rheumatol 69:387–397CrossRefPubMedPubMedCentral

22.

Friedman MA, Winthrop K (2016) Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol 28:330–336CrossRefPubMed

23.

Gilhus NE (2017) Eculizumab: a treatment option for mysthenia gravis? Lancet Neurol 16:947–948CrossRefPubMed

24.

Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570–2581CrossRefPubMed

25.

Gilhus NE, Nacu A, Andersen JB, Owe JF (2015) Myasthenia gravis and risks for comorbidity. Eur J Neurol 22:17–23CrossRefPubMed

26.

Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023–1036CrossRefPubMed

27.

Gui MC, Luo X, Lin J, Li Y, Zhang M, Zhang XF, Yang MS, Wang W, Bu BT (2015) Long-term outcome of 424 childhood-onset myasthenia gravis patients. J Neurol 262:823–830CrossRefPubMed

28.

Guptill JT, Juel VC, Massey JM, Anderson AC, Chopra M, Yi JS, Esfandiari E, Buchanan T, Smith B, Atherfold P, Jones E, Howard JF (2016) Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity 49:472–479CrossRefPubMedPubMedCentral

29.

Holbro A, Jauch A, Lardinois D, Tzankov A, Dirnhofer S, Hess C (2012) High prevalence of infections and autoimmunity in patients with thymoma. Hum Immunol 73:287–290CrossRefPubMed

30.

Hung WL, Lin YH, Wang PY, Chang MH (2011) HIV-associated myasthenia gravis and impacts of HAART: one case report and a brief review. Clin Neurol Neurosurg 113:672–674CrossRefPubMed

31.

Jf B (2017) The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. Nat Rev Immunol 111:1–16

32.

Jing F, Wei D, Wang D, Li N, Cui F, Yang F, Chen Z, Huang X (2013) Lack of Epstein–Barr virus infection in Chinese myasthenia gravis patients. Acta Neurol Scand 128:345–350PubMed

33.

Jones SC, Sorbello A, Boucher RM (2011) Fluoroquinolone-associated myasthenia gravis exacerbation evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf 34:839–847CrossRefPubMed

34.

Kakalacheva K, Maurer MA, Tackenberg B, Munz C, Willcox N, Lunemann JD (2011) Intrathymic Epstein–Barr virus infection is not a prominent feature of myasthenia gravis. Ann Neurol 70:508–514CrossRefPubMed

35.

Kalita J, Kohat AK, Misra UK (2014) Predictors of outcome of myasthenic crisis. Neurol Sci 35:1109–1114CrossRefPubMed

36.

Kanth KM, Solorzano GE, Goldman MD (2016) PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract 6:E17–E19CrossRefPubMedPubMedCentral

37.

Kohling HL, Plummer SF, Marchesi JR, Davidge KS, Ludgate M (2017) The microbiota and autoimmunity: their role in thyroid autoimmune diseases. Clin Immunol 183:63–74CrossRefPubMed

38.

Le P, Rothberg MB (2017) Cost effectiveness of a shingles vaccine booster for currently vaccinated adults in the US. Am J Prev Med 53:829–836CrossRefPubMed

39.

Leis AA, Szatmary G, Ross MA, Stokic DS (2014) West nile virus infection and myasthenia gravis. Muscle Nerve 49:26–29CrossRefPubMed

40.

Liu IJ, Chiu CY, Chen YC, Wu HC (2011) Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem 286:9726–9736CrossRefPubMedPubMedCentral

41.

Liu XQ, Bian SN, Zhang YQ, Zhang LF, Yang QW, Wang P, Xu YC, Shi XC, Zhang Y, Chemaly RF (2016) The characteristics of patients with Mycobacterium tuberculosis blood stream infections in Beijing, China: a retrospective study. BMC Infect Dis 16:750. https://doi.org/10.1186/s12879-016-2084-z CrossRefPubMedPubMedCentral

42.

Ma GK, Brensinger CM, Wu QF, Lewis JD (2017) Increasing incidence of multiply recurrent Clostridium difficile infection in the United States a cohort study. Ann Intern Med 167:152–158CrossRefPubMed

43.

Maniaol AH, Elsais A, Lorentzen AR, Owe JF, Viken MK, Saether H, Flam ST, Brathen G, Kampman MT, Midgard R, Christensen M, Rognerud A, Kerty E, Gilhus NE, Tallaksen CME, Lie BA, Harbo HF (2012) Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. Plos One 7(5):e36603. https://doi.org/10.1371/journal.pone.0036603

44.

Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Strobel P (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12:875–884CrossRefPubMed

45.

Melamed RD, Khiabanian H, Rabadan R (2014) Data-driven discovery of seasonally linked diseases from an electronic health records system. BMC Bioinf 15 (Suppl 6):S3. https://doi.org/10.1186/1471-2105-15-S6-S3 CrossRef

46.

Meyer A, Levy Y (2011) Geoepidemiology of myasthenia gravis (vol 9, pg A383, 2010). Autoimmun Rev 10:811CrossRef

47.

Meyer M, Hols AK, Liersch B, Leistner R, Gellert K, Schalke B, Marx A, Niedobitek G (2011) Lack of evidence for Epstein–Barr virus infection in myasthenia gravis thymus. Ann Neurol 70:515–518CrossRefPubMed

48.

Molko N, Simon O, Guyon D, Biron A, Dupont-Rouzeyrol M, Gourinat AC (2017) Zika virus infection and myasthenia gravis: report of 2 cases. Neurology 88:1097–1098CrossRefPubMed

49.

Morandi E, Jagessar SA, A‘t Hart B, Gran B (2017) EBV infection empowers human B cells for Autoimmunity: role of autophagy and relevance to multiple sclerosis. J Immunol 199:435–448CrossRefPubMed

50.

Munz C, Lunemann JD, Getts MT, Miller SD (2009) Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 9:246–258CrossRefPubMedPubMedCentral

51.

Niller HH, Wolf H, Ay E, Minarovits J (2011) Epigenetic dysregulation of Epstein–Barr virus latency and development of autoimmune disease. Adv Exp Med Biol 711:82–102

52.

O’Leary ST, Kimberlin DW (2017) Update from the advisory committee on immunization practices. J Pediatr Infect Dis Soc 6:311–316CrossRef

53.

Ordas I, Domenech E, Manosa M, Garcia-Sanchez V, Iglesias-Flores E, Penalva M, Canas-Ventura A, Merino O, Fernandez-Banares F, Gomollon F, Vera M, Gutierrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E, Munoz F, Aguirresarobe M, Munoz C, Fernandez L, Calvet X, Jimenez CE, Montoro MA, Mir A, De Castro ML, Garcia-Sepulcre MF, Bermejo F, Panes J, Esteve M, GETECCU ER (2017) Long-term efficacy and safety of cyclosporine in a cohort of steroid-refractory acute severe ulcerative colitis patients from the ENEIDA registry (1989–2013): a nationwide multicenter study. Am J Gastroenterol 112:1709–1718CrossRefPubMed

54.

Perrot X, Bernard N, Vial C, Antoine JC, Laurent H, Vial T, Confavreux C, Vukusic S (2006) Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 67:2256–2258CrossRefPubMed

55.

Prelog M, Egli A, Zlamy M, Hirsch HH (2013) JC and BK polyomavirus-specific immunoglobulin G responses in patients thymectomized in early childhood. J Clin Virol 58:553–558CrossRefPubMed

56.

Ramagopalan SV, Goldacre R, Skingsley A, Conlon C, Goldacre MJ (2013) Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies. BMC Med 11:97. https://doi.org/10.1186/1741-7015-11-97 CrossRefPubMedPubMedCentral

57.

Ramos-Fransi A, Rojas-Garcia R, Segovia S, Marquez-Infante C, Pardo J, Coll-Canti J, Jerico I, Illa I, Myasthenia NMDESSG (2015) Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol 22:1056–1061CrossRefPubMed

58.

Randall KL (2016) Rituximab in autoimmune diseases. Aust Prescr 39:131–134CrossRefPubMedPubMedCentral

59.

Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, Chio A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ (2015) A genome-wide association study of myasthenia gravis. JAMA Neurol 72:396–404CrossRefPubMedPubMedCentral

60.

Romi F, Bo L, Skeie GO, Myking A, Aarli JA, Gilhus NE (2002) Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol 128:82–89CrossRefPubMed

61.

Romi F, Hong Y, Gilhus NE (2017) Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin immunol 49:9–13CrossRefPubMed

62.

Rostaing L, Malvezzi P (2016) Steroid-based therapy and risk of infectious complications. Plos Med 13(5):e1002025. https://doi.org/10.1371/journal.pmed.1002025 CrossRefPubMedPubMedCentral

63.

Salemi S, D’Amelio R (2010) Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol 29:270–314CrossRefPubMed

64.

Schmidt SAJ, Vestergaard M, Baggesen LM, Pedersen L, Schonheyder HC, Sorensen HT (2017) Prevaccination epidemiology of herpes zoster in Denmark: quantification of occurrence and risk factors. Vaccine 35:5589–5596CrossRefPubMed

65.

Sempowski GD, Thomasch JR, Gooding ME, Hale LP, Edwards LJ, Ciafaloni E, Sanders DB, Massey JM, Douek DC, Koup RA, Haynes BF (2001) Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis. J Immunol 166:2808–2817CrossRefPubMed

66.

Seok HY, Shin HY, Kim JK, Kim BJ, Oh J, Suh BC, Kim SY, Kang SY, Ahn SW, Bae JS, Kim BJ (2017) The impacts of influenza infection and vaccination on exacerbation of myasthenia gravis. J Clin Neurol 13:325–330CrossRefPubMedPubMedCentral

67.

Stern A, Green H, Paul M, Vidal L, Leibovici L (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 10:CD005590. https://doi.org/10.1002/14651858.CD005590.pub3 CrossRef

68.

Strezova A, Godeaux O, Aggarwal N, Leroux-Roels G, Lopez-Fauqued M, Van Damme P, Vanden Abeele C, Vastiau I, Heineman TC, Lal H (2017) A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. Vaccine 35:6700–6706CrossRefPubMed

69.

Strijbos E, Huijbers MG, van Es IE, Alleman I, van Ostaijen-ten Dam MM, Bakker J, van Zwet EW, Jol-van der Zijde CM, van Tol MD, Verschuuren JJ (2017) A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis. Vaccine 35:6290–6296CrossRefPubMed

70.

Stubgen JP (2010) Neuromuscular disorders associated with Hepatitis B vaccination. J Neurol Sci 292:1–4CrossRefPubMed

71.

Sugimoto N, Nakajima A, Inoue E, Shidara K, Yamashita H, Mimori A, Tokuda H, Seto Y, Tanaka E, Momohara S, Taniguchi A, Yamanaka H (2017) Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis. Rheumatol Int 37:1871–1878CrossRefPubMed

72.

Trivin C, Tran A, Moulin B, Choukroun G, Gatault P, Courivaud C, Augusto JF, Ficheux M, Vigneau C, Thervet E, Karras A (2017) Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clin Kidney J 10:461–469PubMed

73.

Van Berkel MA, Twilla JD, England BS (2016) Emergency department management of a myasthenia gravis patient with community-acquired pneumonia: does initial antibiotic choice lead to cure or crisis? J Emerg Med 50:281–285CrossRefPubMed

74.

Virot E, Duclos A, Adelaide L, Miailhes P, Hot A, Ferry T, Seve P (2017) Autoimmune diseases and HIV infection a cross-sectional study. Med 96(4):e5769. https://doi.org/10.1097/MD.0000000000005769 CrossRef

75.

Wickramasekaran RN, Jewell MP, Sorvillo F, Kuo T (2017) The changing trends and profile of pneumocystosis mortality in the United States, 1999–2014. Mycoses 60:607–615CrossRefPubMed

76.

Withrock IC, Anderson SJ, Jefferson MA, McCormack GR, Mlynarczyk GSA, Nakama A, Lange JK, Berg CA, Acharya S, Stock ML, Lind MS, Luna KC, Kondru NC, Manne S, Patel BB, de la Rosa BM, Huang KP, Sharma S, Hu HZ, Kanuri SH, Carlson SA (2015) Genetic diseases conferring resistance to infectious diseases. Genes Dis 2:247–254CrossRef

77.

Wolfe GIKH, Aban IB, Minisman G et al (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375:511–522CrossRefPubMedPubMedCentral

78.

Wong PKK, Bagga H, Barrett C, Hanrahan P, Johnson D, Katrib A, Leder K, Marabani M, Pentony P, Riordan J, White R, Young L (2017) A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia. Intern Med J 47:491–500CrossRefPubMed

79.

Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, Yamada M (2004) Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain–Barre syndrome. Proc Natl Acad Sci USA 101:11404–11409CrossRefPubMedPubMedCentral

80.

Zlamy M, Almanzar G, Parson W, Schmidt C, Leierer J, Weinberger B, Jeller V, Unsinn K, Eyrich M, Wurzner R, Prelog M (2016) Efforts of the human immune system to maintain the peripheral CD8+ T cell compartment after childhood thymectomy. Immun Ageing 13:3. https://doi.org/10.1186/s12979-016-0058-z CrossRefPubMedPubMedCentral

81.

Zlamy M, Wurzner R, Holzmann H, Brandstatter A, Jeller V, Zimmerhackl LB, Prelog M (2010) Antibody dynamics after tick-borne encephalitis and measles-mumps-rubella vaccination in children post early thymectomy. Vaccine 28:8053–8060CrossRefPubMed

Titel: Myasthenia gravis and infectious disease
verfasst von: Nils Erik Gilhus
Fredrik Romi
Yu Hong
Geir Olve Skeie
Publikationsdatum: 25.01.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 6/2018
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-8751-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Myasthenia gravis and infectious disease

Abstract

Background and purpose

Methods

Results and conclusions

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Update Neurologie

Springer Medizin

Abstract

Background and purpose

Methods

Results and conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study

Resistance to eye opening in patients with disorders of consciousness

Monoclonal antibodies for migraine: an update

Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study

Similarities and differences between infantile and early childhood onset vanishing white matter disease

Letter to the editor: insular stroke presenting with acute onset of pain

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Update Neurologie